Nuvo Pharmaceuticals Inc MRVFF

proformas update

[lscfa]

9 months 2018 ebitda $23 mil.....12 months 2017 ebitda $23.8 mil......  


https://www.nuvopharmaceuticals.com/wp-content/uploads/2019/03/2019-03-15-Nuvo_BAR_Presentation.pdf

[ValueCap]

Looks good! Can anyone explain how the IFRS 15 works? 

[lscfa]

In Nuvo’s case it’s pointing out that the minimum $7.5 million Horizon royalty due each year will not show up as revenue but rather as a reduction to an asset. The payment will show up on the cash flow statement. The rule does an awful job at reflecting economic reality because each year the revenue is $7.5 million lower than it really is.  This is happened with EUO. The co. sold a business

[lscfa]

This will create some big spreads for basic and diluted eps. I calc. cash eps because amort is non-recurring and non-cash.     Proforma 2017 Ebitda 23.8 Debt Int.  -6.3 Ebt  17.5 30% tax

[lscfa]

Looking forward......     Proforma 2017 2019 est. Bloom Burton Ebitda 23.8 32.4 Debt Int.  -6.3 -6.3 Ebt  17.5 26.1

[ronz]

Im not getting my hopes up. This stock doesnt seem to have "ANY" interest whats so ever anymore. News goes completely ignored, it barely even trades anymore, and the price basically flat lines or continues to very slowly lose a little bit every few days but over a period of time, it has been a significant drop from its heyday! Nobody trusts this management team, and they cant even

[rationalexuberance]

I know what you mean.....no interest in the stock whatsoever....just listened to the c.c and not one question in the Q&A; on the other hand, this is precisely the time to buy the stock, not after it has run; hopefully we will see a strong Q2 and Q3 when their product cycle hits their seasonal highs....

[lscfa]

I wanted to hear about synergies between the merged entities. Surely there will be some elimination of duplicate expenses and thus cost savings on an ongoing basis.